OncLive

1 day ago | onclive.com | Chris Ryan

The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) harboring high c-MET protein overexpression who have received a prior systemic therapy.

1 day ago | onclive.com | Chris Ryan

The FDA has approved belzutifan (Welireg) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma. The regulatory decision was supported by findings from the phase 2 LITESPARK-015 trial (NCT04924075), which showed that patients achieved an overall response rate (ORR) of 26% (95% CI, 17%-38%). The median duration of response (DOR) was 20.4 months (95% CI, 8.3-not reached).

1 day ago | onclive.com | Courtney Flaherty

The combination of AlloNK (AB-101) plus rituximab (Rituxan) produced high complete response (CR) rates and prolonged responses beyond 12 months in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL), according to updated data from a phase 1/2 trial(NCT04673617) presented at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting.1Among patients who received AlloNK plus rituximab and were naive to prior CAR T-cell therapy (n = 14), the CR rate was 64%.

1 day ago | onclive.com | Chris Ryan

Generic, AB-rated formulations of eltrombopag (Promacta) as an oral suspension and a tablet are now commercially available for the treatment of select patients with severe aplastic anemia and immune thrombocytopenia.1,2 Specifically, the generic oral suspension and tablet formulations of eltrombopag are approved in the following indications: For patients with severe aplastic anemia who are insufficiently responsive to immunosuppressive therapy For patients 1 year of age and older with...

1 day ago | onclive.com | Maurie Markman

his commentator could think of no better way to begin a brief discussion addressing the current unreality of cancer care finances in the US than to invoke the theme of Hans Christian Andersen’s famous childhood tale “The Emperor’s New Clothes.”1 “Oh, how beautiful are our Emperor’s new clothes.... In fact, no one would admit that he could not see these clothes, which everyone seemed to think so beautiful, for fear he would be called a simpleton or unfit for his office....